- May 10, 2021 Chugai Reached Agreement with Japanese Government regarding Investigational Antibody Cocktail (casirivimab and imdevimab) for COVID-19
- May 10, 2021 Chugai Discontinues Marketing of Photodynamic Diagnostic Agent "ALAGLIO® Divided Granules 1.5g"
- May 06, 2021 Research Collaboration by Chugai, the University of Tokyo and RIKEN on Functional Genome Database Published in Cell
- Apr 26, 2021 CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Apr 22, 2021 Chugai Announces 2021 1st Quarter Results